Published
## Filings that contain financial statements - Form 8-K filed July 31, 2026 (accession 0001551152-26-000023): Exhibit 99.1 furnishes AbbVie's second-quarter and six-month 2026 GAAP consolidated statements of earnings, key-product revenue tables and GAAP-to-non-GAAP reconciliations for the periods ended June 30, 2026 (with June 30, 2025 comparatives). - Form 8-K filed April 29, 2026 (accession 0001551152-26-000013): Exhibit 99.1 furnishes the first-quarter 2026 GAAP consolidated statement of earnings, key-product revenue table and reconciliations for the quarter ended March 31, 2026 (with March 31, 2025 comparatives). - Form 8-K filed February 4, 2026 (accession 0001551152-26-000004): Exhibit 99.1 furnishes the fourth-quarter and full-year 2025 GAAP consolidated statements of earnings, key-product revenue tables and reconciliations for the periods ended December 31, 2025 (with 2024 comparatives). - Form 8-K filed October 31, 2025 (accession 0001551152-25-000047): Exhibit 99.1 furnishes the third-quarter and nine-month 2025 GAAP consolidated statements of earnings, key-product revenue tables and reconciliations for the periods ended September 30, 2025 (with 2024 comparatives). ## Apogee Therapeutics acquisition - **September 3, 2026** — AbbVie completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion; Apogee's common stock ceased trading prior to market open the same day. AbbVie said the deal will reduce adjusted diluted EPS by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion beginning in 2032, and reaffirmed its 2026 full-year adjusted diluted EPS guidance of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88 (Form 8-K, accession 0001104659-26-104940). - **June 22, 2026** — AbbVie and Apogee announced a definitive merger agreement under which AbbVie will acquire all outstanding Apogee shares for $135.11 per share in cash (approximately a 49% premium to Apogee's June 18, 2026 closing price), a total equity value of approximately $10.9 billion (implied transaction value of approximately $10.1 billion net of Apogee's estimated cash and marketable securities). The deal adds Apogee's immunology pipeline, led by zumilokibart (APG777, an IL-13 antibody for atopic dermatitis) and APG273 (an IL-13/TSLP combination for asthma). AbbVie said it would fund the transaction with debt, expected the deal to close in the third quarter of 2026, and to be $0.14 dilutive to adjusted diluted EPS in 2026 and approximately $0.46 dilutive in 2027, with accretion beginning in 2032 (Form 8-K, accession 0001104659-26-076067, and Exhibit 99.2 investor presentation). ## Debt financing tied to the Apogee acquisition - **August 18, 2026** — AbbVie closed an underwritten public offering of $10.0 billion aggregate principal amount of senior notes across nine tranches (floating-rate notes due 2028 and fixed-rate notes due 2028 through 2066), issued under Supplemental Indenture No. 13. AbbVie said the offering was conducted in connection with the Apogee acquisition and that proceeds would fund a portion of the cash consideration for Apogee, with any excess for general corporate purposes (Form 8-K, accession 0001104659-26-098367). - **August 4–5, 2026** — AbbVie entered into the underwriting agreement for the notes offering above; expected net proceeds of approximately $9.93 billion, intended to fund a portion of the Apogee cash consideration and reduce commitments under a $10.0 billion 364-day delayed-draw term loan facility entered into in connection with the acquisition (Form 8-K, accession 0001104659-26-091269). ## Other capital markets activity - **March 4, 2026** — AbbVie closed an underwritten public offering of $8.0 billion aggregate principal amount of senior notes across seven tranches (floating-rate notes due 2028 and fixed-rate notes due 2028 through 2066), issued under Supplemental Indenture No. 12. Net proceeds of approximately $7.95 billion were intended to repay amounts outstanding under a $4.0 billion 364-day delayed-draw term loan facility maturing in May 2026 (of which $2.0 billion was then outstanding) and for general corporate purposes (Form 8-K, accession 0001104659-26-023534; underwriting agreement entered February 24, 2026, accession 0001104659-26-020643). ## Earnings and guidance - **July 31, 2026 — second-quarter 2026 results.** Net revenues were $16.990 billion, up 10.2% reported (9.5% operational). GAAP diluted EPS was $2.03 (up 290.4%) and adjusted diluted EPS was $3.65 (up 22.9%), including a $0.17 per-share unfavorable impact from acquired IPR&D and milestones expense. Immunology net revenues were $8.786 billion (Skyrizi $5.505 billion, Rinvoq $2.525 billion, Humira $756 million). AbbVie updated its full-year 2026 adjusted diluted EPS guidance to $13.87–$14.07 (from $13.91–$14.11), reflecting the anticipated $0.14 per-share dilution from the pending Apogee acquisition partly offset by $0.10 of overperformance (Form 8-K, accession 0001551152-26-000023). - **July 6, 2026** — AbbVie disclosed preliminary second-quarter 2026 acquired IPR&D and milestones expense of $291 million pre-tax (an unfavorable $0.17 per-share impact to both GAAP and adjusted EPS), updating full-year 2026 adjusted diluted EPS guidance to $13.91–$14.11 and second-quarter guidance to $3.57–$3.61 (Form 8-K, accession 0001551152-26-000021). - **April 29, 2026 — first-quarter 2026 results.** Net revenues were $15.002 billion, up 12.4% reported (10.3% operational). GAAP diluted EPS was $0.39 (down 45.8%) and adjusted diluted EPS was $2.65 (up 7.7%), including a $0.41 per-share unfavorable impact from acquired IPR&D and milestones expense. Immunology net revenues were $7.290 billion (Skyrizi $4.483 billion, Rinvoq $2.119 billion, Humira $688 million). AbbVie raised full-year 2026 adjusted diluted EPS guidance to $14.08–$14.28 from $13.96–$14.16 (Form 8-K, accession 0001551152-26-000013). - **April 3, 2026** — AbbVie disclosed preliminary first-quarter 2026 acquired IPR&D and milestones expense of $744 million pre-tax (an unfavorable $0.41 per-share impact), updating full-year 2026 adjusted diluted EPS guidance to $13.96–$14.16 (Form 8-K, accession 0001551152-26-000011). - **February 4, 2026 — fourth-quarter and full-year 2025 results.** Full-year net revenues were $61.160 billion, up 8.6% reported. Full-year GAAP diluted EPS was $2.36 (down 1.3%) and adjusted diluted EPS was $10.00 (down 1.2%), including a $2.76 per-share unfavorable impact from 2025 acquired IPR&D and milestones expense. Fourth-quarter net revenues were $16.618 billion, up 10.0%; GAAP diluted EPS was $1.02 and adjusted diluted EPS was $2.71. AbbVie issued initial full-year 2026 adjusted diluted EPS guidance of $14.37–$14.57, excluding any impact from future acquired IPR&D and milestones expense (Form 8-K, accession 0001551152-26-000004). The same filing disclosed a voluntary agreement with the U.S. administration under which AbbVie will provide lower Medicaid prices and expanded direct-to-patient affordability programs, commit $100 billion to U.S. R&D and capital investment (including manufacturing) over the next decade, and receive a three-year exemption from tariffs and future pricing mandates; it also disclosed a definitive agreement with West Pharmaceutical Services for AbbVie to acquire a device-manufacturing facility in Tempe, Arizona, and associated intellectual property. - **January 7, 2026** — AbbVie disclosed preliminary fourth-quarter 2025 acquired IPR&D and milestones expense of approximately $1.3 billion pre-tax (an unfavorable $0.71 per-share impact), updating full-year 2025 adjusted diluted EPS guidance to $9.90–$9.94 (Form 8-K, accession 0001551152-26-000002). - **October 31, 2025 — third-quarter 2025 results.** Net revenues were $15.776 billion, up 9.1% reported. GAAP diluted EPS was $0.10 (down 88.6%) and adjusted diluted EPS was $1.86 (down 38.0%), including a $1.50 per-share unfavorable impact from acquired IPR&D and milestones expense. AbbVie raised full-year 2025 adjusted diluted EPS guidance to $10.61–$10.65 from $10.38–$10.58. The board also declared a 5.5% increase in the quarterly cash dividend, to $1.73 per share from $1.64 per share, beginning with the dividend payable February 17, 2026, to shareholders of record January 16, 2026 (Form 8-K, accession 0001551152-25-000047). The same release disclosed that AbbVie had completed its acquisition of Capstan Therapeutics (an in vivo CAR-T/lipid-nanoparticle platform for autoimmune disease) and completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, a Phase 2 psychedelic compound for major depressive disorder. - **October 3, 2025** — AbbVie disclosed preliminary third-quarter 2025 acquired IPR&D and milestones expense of approximately $2.7 billion pre-tax (an unfavorable $1.50 per-share impact), updating full-year 2025 adjusted diluted EPS guidance to $10.38–$10.58 (Form 8-K, accession 0001551152-25-000043). ## Governance - **May 8, 2026** — At AbbVie's annual meeting of stockholders, all four Class II director nominees were elected, Ernst & Young LLP's appointment as auditor was ratified, and the say-on-pay advisory vote passed. A management proposal to eliminate supermajority voting requirements from the certificate of incorporation was not approved, and a stockholder proposal to require an independent board chair was not approved (Form 8-K, accession 0001104659-26-059484). ## West Pharmaceutical Services device-facility acquisition - **July 2026** — AbbVie's acquisition of West Pharmaceutical Services' device-manufacturing facility in Tempe, Arizona, and associated intellectual property — for which AbbVie disclosed a definitive agreement on February 4, 2026 (Form 8-K, accession 0001551152-26-000004) — closed. AbbVie disclosed no purchase price. The closing is disclosed only in the Form 10-Q for the quarter ended June 30, 2026 (accession 0001551152-26-000026), MD&A "Recent Events"; no 8-K covers the closing.